Navigation Links
GeNO LLC Announces Senior Management Appointment

WALTHAM, Mass., Aug. 27, 2013 /PRNewswire/ -- GeNO LLC, a privately-held biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases, today announced that Kurt A. Dasse, Ph.D., currently serving as president and a member of the company's Board of Managers, has been appointed CEO of the Company.  Dr. David Fine will continue to serve GeNO as executive chairman and chief scientific officer.

"Dr. Dasse has significant international experience with the use of inhaled nitric oxide to minimize the risk of right heart failure following the treatment of patients undergoing the implantation of Left Ventricular Assist Devices (LVADs). This appointment will strengthen the company's focus on developing and obtaining regulatory approvals for its innovative and cost-effective platforms for generating nitric oxide therapy in the treatment of multiple diseases and conditions," said David Fine, GeNO founder and executive chairman. "I am thrilled to hand over the role of CEO to Kurt."

"I believe GeNO is well positioned to make a significant impact on the medical treatment of patients worldwide who suffer from pulmonary and cardiac diseases," said Dasse. "I am honored and excited to lead a highly talented group at GeNO committed to delivering the next generation of inhaled nitric oxide products, including a portable solution, designed to benefit a large patient population."

Dasse, who will continue to serve on the company's Board of Managers, has spent nearly 30 years researching and developing therapies for cardiopulmonary disorders, and has developed and commercialized devices and therapies for the treatment of heart, lung and renal failure. He joined GeNO as a member of the Board of Managers in 2007, and was appointed executive vice president in 2011 and president in 2012.

In 2001 Dasse co-founded Levitronix LLC, the developer of the CentriMag LVAD system, where he became president and CEO in 2006. Earlier in his career, Dasse was chief scientist and vice president of Thermo Electron Corporation's $700-million Biomedical Group. He was also one of the founding officers of Thermo Cardiosystems and played a key role in commercializing one of the first implantable ventricular assist systems for end-stage heart failure patients. Dasse received his doctorate in physiology from Boston University and his bachelor's degree in biology from the University of Massachusetts. He has written more than 100 journal articles and multiple book chapters, and holds numerous patents.


GeNO LLC is a privately-held biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases.  GeNO is currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting.  GeNO's technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians and other end-users with a user-friendly solution.

CONTACT: Brian Heffron,
(781) 799-9568

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sihuan Pharmaceutical Announces 2013 Interim Results
2. Echo Therapeutics Announces Management Changes
3. ConvaTec Announces 2013 Second Quarter Earnings Call
4. Sam Solakyan, CEO of Vital Imaging Announces purchase of cutting edge equipment
5. Yew Bio-Pharm Group Announces Coverage by S&P Capital IQ
6. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
7. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
8. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
9. VirtualScopics Announces 1-for-10 Reverse Stock Split
10. Allscripts Announces Winners of the Open App Challenge
11. CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2013
Post Your Comments:
(Date:11/30/2015)... , Belgium , Nov. 30, 2015 ... sciences company focused on developing blood-based diagnostic tests for a ... the Company will present at the LD Micro Conference, which ... Los Angeles, CA. Attending from VolitionRx will be ... Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare and ... Life Sciences Report 2015 . --> Pharmaboardroom releases its ... Latin America , a country of over ... a country of over 122 million people. --> It ... pharmaceuticals, or life sciences insights into the second largest pharma and ...
(Date:11/30/2015)... 2015 Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ... Kentucky Breast Care to increase collaboration with sub-specialists around ... patients. --> Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone will experience death ... or animal pass away, death lives among us. It is your perspective, however, that ... family of 11 children, author T Sky understands that she may see death more ...
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today that ... Their Ecosystem empowers dentists to make complex business decisions by providing the tools and ... a free fee survey with 10 procedures customized by zip code. , The ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in ... TIGR® Matrix is a long-term resorbable surgical mesh intended to support and reinforce ...
(Date:11/30/2015)... ... November 30, 2015 , ... SIMmersion’s ability ... to the medical schools of the future. To reach an audience of key ... 2015 ChangeMedEd conference in Chicago, organized by the American Medical Association. , ...
(Date:11/30/2015)... CALIF. (PRWEB) , ... November ... ... ( ), a leading provider of enterprise Time and Attendance/Workforce Management ... status in the Microsoft Partner Program with competencies in the Application Development, ...
Breaking Medicine News(10 mins):